MAC-Team

Items filtered by date: January 2014
22 January 2014 In Agri & Biotech

Biobased productsThis brief EU Industrial policy overview for the Bio-based products sector is an extract of the report published January 22, 2014. This staff working document illustrates trends and the impact of the crisis on production, investment, productivity, employment, skills and innovation. It also describes the EU performance in the international arena and considers possible benefits from improvements in the internal market regulations.

Estimates suggest that in 2010 bio-based products accounted for 10% of sales within the global chemical industry, representing 125 billion dollars in value. However, the share could rise to as much as 20% depending on the development of technologies, feedstock prices and policy framework.
Based on an assessment presented in the 2012 Commission Communication on the bio-economy strategy, the segment of bio-based industries in the EU currently represents approximately 57 billion € in annual turnover with 300,000 jobs involved. Bio-based industries encompass the following main categories: Bio-based lubricants, polymers, surfactants, solvents and chemical building blocks; Enzymes and Biofuels, estimated respectively at 50 billion, 0.8 billion and 6 billion € annual turnover.
Europe is technologically well positioned to spearhead the switch to a low carbon society with strong agricultural, agro-food and forestry sectors and world-leading companies in the plant breeding, biotech and chemical/biochemical, engineering and energy industries.
Although the EU industry has already started to make significant investments in bio-refineries - e.g. in France, Germany, Finland, Netherlands, Denmark, Italy, Spain – this has so far been done in a fragmented manner. Europe needs to maintain its competitive edge by consolidating and capitalizing its prominent knowledge base and creating the necessary framework conditions for industry to increase its investments in Europe.

22 January 2014 In Agri & Biotech

pharmaceutical sectorThis brief EU Industrial policy overview for the Pharmaceutical sector is an extract of the report published January 22, 2014. This staff working document illustrates trends and the impact of the crisis on production, investment, productivity, employment, skills and innovation. It also describes the EU performance in the international arena and considers possible benefits from improvements in the internal market regulations.

Europe has traditionally been a world leader in the pharmaceutical sector. This high-tech industry presents an excellent overall performance and has been particularly resilient to the crisis and therefore, it can be considered as one of the gems of the European economy. The reasons why a viable European pharmaceutical industry is of the utmost importance are four-fold:
1°) it contributes to the health and the quality of life of our citizens by providing remedies to an ever-increasing number of patients. As the burden of disease is likely to increase as a consequence of the ageing European population it is to be expected that the 9.5% GDP spending on healthcare costs, including pharmaceutical treatment, on average across OECD countries in 2010 will increase significantly in the coming years.
2°) the healthcare sector and in particular the pharmaceutical industry is of economic significance, as demonstrated by €157 billion in annual turnover and 660,000 employees (of whom 110,000 are researchers).
3°) the European pharmaceutical industry serves as a major contributor to the EU's position as a successful trading power. In fact, the European Union is the world's major trader in medicinal and pharmaceutical products enjoying a trade surplus of EUR 56 billion in 2012.
4°) the world market of medical products is a growth market, i.e. global spending on medicines will grow to nearly $1.2 trillion by 2016. While the developed markets are expected to grow slowly due to the sustained impact of the global economic crisis, emerging markets will become the major sources of demand.

22 January 2014 In Agri & Biotech

Agri fieldsThis brief EU Industrial policy overview for the Agri-food sector is an extract of the report published January 22, 2014. This staff working document illustrates trends and the impact of the crisis on production, investment, productivity, employment, skills and innovation. It also describes the EU performance in the international arena and considers possible benefits from improvements in the internal market regulations.

With an annual turnover over EUR 1 trillion and around 4 million employees, the agri- food industry is part of a complex supply chain, which encompasses also agriculture and distributive trade. Taken as a whole, this value chain generates a total value added of € 715 billion per year — almost 6% of the EU Gross Domestic Product. On average, 15% of household expenditure is on food and drink. The sector not only feeds people,it also responds to cultural, health, ethical demands and many other qualities that consumers demand from their food, including convenience.
Moreover, the EU is the world's biggest exporter and importer of agricultural and food products and accounts for about 19% of total global export flows.

12 January 2014 In Current Projects

WikiNomics projectWikiNomics is a Lifelong Learning Programme project co-financed by the European Union for 2 years under the Leonardo da Vinci programme, started in November 2013. 
The Wikinomics project aims to foster key competences required for employability in the constantly changing environments of the world of work. It sets free-culture and wiki methodologies as the basis for an innovative pedagogical methodology.

10 January 2014 In Skills & Competences

RDAThe Research Data Alliance (RDA) builds the social and technical bridges that enable open sharing of data.
The RDA vision is researchers and innovators openly sharing data across technologies, disciplines, and countries to address the grand challenges of society.

03 January 2014 In Skills & Competences

ScienceExchangeScience Exchange, a science services marketplace, links people in research institutions that have specialized service offerings with researchers that need access to those core services. "Science Exchange was developed to create a marketplace for scientific collaboration where researchers can order experiments from the world's best labs," says Elizabeth Iorns, Science Exchange CEO. "The premise is that this collaboration would, in turn, increase the efficiency of scientific research."

You are here: Home MAC Network Items filtered by date: January 2014